home / stock / alxo / alxo news

ALXO News and Press, ALX Oncology Holdings Inc. From 03/02/22

Stock Information
Company Name: ALX Oncology Holdings Inc.
Stock Symbol: ALXO
Market: NASDAQ
Website: alxoncology.com
Menu
ALXO ALXO Quote ALXO Short ALXO News ALXO Articles ALXO Message Board
Get ALXO Alerts

News, Short Squeeze, Breakout and More Instantly...
ALXO - ALX Oncology begins dosing in phase 2/3 trial of evorpacept in gastric cancer

ALX Oncology (NASDAQ:ALXO) said the first patient was dosed in a  phase 2/3 ASPEN-06 trial evaluating its drug evorpacept and Eli Lilly's (NYSE:LLY) Cyramza (ramucirumab), added to trastuzumab and paclitaxel to treat patients with HER2-positive gastric cancer or gastroesophagea...
ALXO - ALX Oncology Announces First Patient Dosed in ASPEN-06, a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer

SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced the first patient ...

ALXO - ALX Oncology GAAP EPS of -$0.70 misses by $0.08

ALX Oncology press release (NASDAQ:ALXO): Q4 GAAP EPS of -$0.70 misses by $0.08.  Cash and cash equivalents as of December 31, 2021 were $363.7 million. For further details see: ALX Oncology GAAP EPS of -$0.70 misses by $0.08

ALXO - ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the fourth quar...
ALXO - ALX Oncology Is Turning Into An Also-Ran In Anti-CD47

2 poor data announcements did not help the stock. LSV sold off a major chunk. ALXO is increasingly looking like an also-ran. For further details see: ALX Oncology Is Turning Into An Also-Ran In Anti-CD47

ALXO - ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that the U.S. Food and Drug Administ...

ALXO - Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer

Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to cancer, across the world. The high mortality rates are pr...
ALXO - ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022

SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today provided a corporate update and highlighted ke...

ALXO - ALX Oncology to Present at the 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, Pres...

ALXO - Indie Semiconductor plunges as CFO sells shares worth $2.4M

Indie Semiconductor (INDI -5.4%) shares plummets after the company disclosed a sale of shares by CFO Thomas Schiller. Thomas Schiller sold 200,00 shares of the company's common stock at $11.85 for $2.4M. Form 4 A look at INDI's ownership composition: For further details see: I...
Previous 10 Next 10